Key Takeaways
- Steady 9% growth, margin leap: Revenue of INR882 crore grew ~9% YoY, while operating EBITDA margin jumped 350 bps to 28.5%, landing at the higher end of the guided range.
- Chronic is the engine, acute is the drag: Domestic chronic therapies grew 14% in Q2, outpacing the IPM by 500 bps, but the GI-focused acute portfolio grew only 6% as lower infections hit Rantac and Metrogyl.
- CDMO doubles down: The CDMO business contributed INR115 crore in Q2 and is now ~12% of revenue, with management targeting $100 million in the mid-to-long term.
- South Africa reset complete: A deliberate INR120 crore annualized haircut from exiting low-margin government tender business is now in the base, with the focus shifting to private market and consumer launches.
- What to watch next quarter: Whether the acute portfolio recovers as seasonality normalizes, the pace of CDMO’s march toward the $100 million target, and any M&A deployment given the stated “buy versus build” philosophy.
Domestic Business: Chronic Strength, Acute Softness
- Chronic outperformance sustained: J.B. grew 14% YoY in chronic therapies in Q2 vs IPM chronic growth of 9%, and 18% for H1 vs IPM chronic at 10%. The gap is driven by the Cilacar franchise and acquired brands like Razel.
- Acute portfolio dragged by GI: The acute portfolio grew only 6% in Q2, with Rantac and Metrogyl growing 5–7%. Management attributed this to lower GI infections due to humidity and weather patterns, calling it fortunate for mankind but unfortunate for the business.
- Big brands scaling: Cilacar franchise is nearing INR600 crore, Rantac INR400 crore, Metrogyl crossed INR300 crore, and Sporlac became a INR100 crore franchise, now ranked 336.
- Cilacar lifecycle management: Cilacar T (INR120 crore) targets diabetic hypertensives, while new combinations like Cilnidipine plus Metoprolol dual and triple combos aim to grow the category where J.B. holds ~50% market share.
- Volume and pricing evenly split: India growth came from a roughly even split of volume and pricing, with volume at ~5–6% and new introductions counted within volume.
Nikhil Chopra: "Unfortunately for us and fortunately for the betterment of the mankind and humidity that people did not suffer from the GI infections. That is why you don't see the traction."
CDMO: The Second Growth Engine
- Revenue nearly doubled: The CDMO business has almost doubled in the last 12–18 months, contributing INR115 crore in Q2 and now representing ~12% of overall revenue.
- $100 million target: Management wants to take the CDMO business to ~$100 million in ~3 years, up from ~$50 million last year, through exploring more geographies with the existing portfolio, diversifying into new products, and delivering cost savings on existing products.
- New launches in pipeline: 2–3 new CDMO launches are expected next year, with a gestation period of 24–30 months, meaning revenue contribution likely in the second half of next year.
- Quarterly pattern: H1 typically does 60% of CDMO revenue, so some softness is expected in Q3, with Q4 returning to current levels.
- Client lifecycle management: Plans with key clients include lifecycle management of existing brands and introduction of new portfolios, supporting continued growth into FY25.
Margins & Cost Structure
- Gross margin up 350 bps YoY: The improvement came from a favorable product mix, the acquired Razel brand (insourced manufacturing improved its own margin), and stable raw material prices.
- Operating EBITDA at 28.5%: This landed on the higher side of the previously guided 25–27% range, aided by cost containment and translation of good performance. Management indicated this higher-side outcome should be taken as the new guidance.
- Raw material stability: Prices are much better than 10 months ago and have been stable for the last 4–6 months, with no significant change expected in the next 2–3 months.
- Chronic mix driving margin: The improving chronic mix in India and acquired assets are the structural drivers of gross margin expansion.
- Productivity target: Management expects productivity to touch INR7 lakh this year and aims to inch it up further while growing at 10–12% next year, with no plans to add to the 2,200-strong medical rep force.
Nikhil Chopra: "Fortunately, Rahul for us, I think in the first half of the year we have been on the higher side of the guidance that we have been giving. So, you can take that as a new guidance from us."
International Business & South Africa Reset
- Ex-South Africa growth healthy: Excluding South Africa, the international business grew double-digit in Q2 and mid-teens in H1, driven by a curated portfolio in selected markets.
- South Africa haircut taken: Management deliberately let go of ~INR120 crore annualized in low-margin government tender business, taking a INR30 crore hit in Q2 and INR60 crore in H1. The base is now reset.
- Shift to private market: The South Africa strategy now focuses on the private market, consumer business, lozenges launches, and working with pharmacy chains like Clicks and Dis-Chems.
- Cautious international stance: Management remains cautious on international markets due to geopolitical situations, driving a curated rather than broad-based portfolio approach.
- Philippines entry distant: The Philippines is a very early starting point, with nothing material expected for 1–2 years.
Nikhil Chopra: "So South Africa, we have taken a haircut of around... you should assume that it should be close to around Rs.120 crore."
Capital Allocation: M&A and “Buy Versus Build”
- Buy versus build philosophy: Management conceptually does not believe in starting from scratch in India, preferring to acquire assets with a good starting point and then scale them.
- M&A criteria: The company looks for opportunities with synergy, a payback period close to 7–8 years, and quality assets, having invested ~$200 million across four acquisitions that bought ~INR275 crore in India revenues.
- Judicious capital allocation: Management emphasized being disciplined on valuations, stating they do not believe in acquiring top line by paying a higher multiple, and pointed to their track record versus other industry deals.
- No specifics on size or valuations: When pressed on potential acquisition size, current valuations, and whether deals would be bolt-on or larger, management declined to comment, calling it difficult to give specific commentary.
- Land acquisition for lozenges: INR50 crore spent on land adjacent to the current unit to double lozenges capacity in 2–3 years, with packaging throughput being debottlenecked by end of December.
Kunal Khanna: "I think the key takeaway for all of us is if you compare the acquisitions which we have made versus some of the other acquisitions which have happened, one will clearly understand that we have been judicious about our capital allocation strategy, right. So, we just don't believe in acquiring top line and paying a higher multiple."
Brand & Portfolio Updates
- Azmarda steady-state achieved: The market has grown from ~10 lakh units/month pre-LOE to ~16–18 lakh units/month currently. J.B. maintains 16–18% market share despite price erosion, with a steady-state run-rate close to the forecast of 1.4–1.5 lakh units/month. Volume gains have offset a significant percentage of the price decline.
- Razel margin contribution: The acquired brand contributed well to gross margin improvement after insourcing into J.B.’s own manufacturing site and shifting sources.
- Respiratory nebulization launch: A nebulization range was launched with ~INR1 crore in the season, but the company has no plans to enter the inhalation space.
- Pediatrics ambition: The range of the pediatric portfolio is expected to help double the business mid-to-long-term.
- Patient-centric campaigns: Campaigns for home blood pressure monitoring and adherence models are being rolled out to support the Cilacar franchise, though no timeline was specified.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Domestic growth | 12–14% growth, 200–300 bps above IPM (8–12%) | Ongoing |
| Operating EBITDA margin | Higher side of 25–27% range; H1 outcome of 28.5% treated as new guidance | Ongoing |
| CDMO revenue target | ~$100 million (from ~$50 million last year) | ~3 years (mid-to-long term) |
| India + CDMO sales mix | 75–80% of overall sales | ~3 years (mid-to-long term) |
| International growth (ex-SA reset) | Double-digit (~12%) | Next year |
| CDMO new launches | 2–3 new launches; gestation 24–30 months | Second half of next year |
| Productivity | INR7 lakh; inch up thereafter with 10–12% growth | This year and next |
| South Africa base reset | INR120 crore annualized haircut absorbed; base reset | Complete |
| Lozenges capacity | Double capacity on newly acquired adjacent land | 2–3 years |
| Field force | No addition to 2,200 reps | Near future |
Key Metrics
| Metric | Q2 FY24 |
|---|---|
| Revenue | ₹882 cr, up ~9% YoY |
| Gross margin | Up 350 bps YoY |
| Operating EBITDA margin | 28.5%, up from 25% in Q2 FY23 |
| Operating EBITDA margin (H1 FY24) | 27.8%, up from 24.6% in H1 FY23 |
| Operating EBITDA (H1 FY24) | ₹494 cr, up from ₹392 cr in H1 FY23 |
| Operating cash flow (H1 FY24) | ₹421 cr, up from ₹279 cr in H1 FY23 |
| Domestic revenue | ₹481 cr, up 11% YoY |
| International business revenue | ₹401 cr |
| CDMO revenue | ₹115 cr |
| Gross debt | ₹427 cr as of Sep 30, 2023, down from ₹548 cr as of Mar 31, 2023 |
| Net debt | ₹18 cr as of Sep 30, 2023, down from ₹266 cr as of Mar 31, 2023 |
| CAPEX (H1 FY24) | ₹93 cr; full-year estimate ₹145 cr |
| IPM rank growth (MAT Sep 2023) | ~18%, fastest growing in Top 25 vs IPM growth of 10% |
| Chronic segment growth (MAT Sep 2023) | 18% YoY, fastest in Top 25 vs IPM chronic growth of 12% |
| Domestic chronic mix | 52–53% |
| Acute portfolio growth (Q2 FY24) | ~6%; Rantac, Metrogyl franchise grew 5–7% |
| Cilacar franchise revenue | Nearing ₹600 cr |
| Rantac franchise revenue | ₹400 cr |
| Metrogyl franchise revenue | Crossed ₹300 cr |
| Sporlac brand rank | 336, close to entering top 300 |
| South Africa revenue haircut (annualized) | ~₹120 cr; ~₹30 cr in Q2 |
| Medical reps | ~2,200, meeting ~2.5 lakh doctors |
| Rep productivity (expected FY24) | ~₹7 lakh |
| Lozenges manufacturing throughput | 17–18 cr lozenges/month; packaging 12–13 cr |
| Azmarda market share | 16–18% |
| Azmarda market volume | 16–18 lakh units/month, up from ~10 lakh pre-LOE |
| Razel run rate | ~₹6 cr, up from ~₹4 cr at acquisition |
| Pediatrics business | ~₹150 cr annually |
| Domestic + CDMO combined share | ~65–67% currently; target 75–80% in ~3 years |
| CDMO business target | $100 million in ~3 years |
| International business growth target (next year) | ~12% (double digit) |
| EBITDA margin guidance | 25–27%, trending toward upper side |